Conserved immunogens in prime-boost strategies for the next-generation HIV-1 vaccines

Expert Opinion on Biological Therapy

Volumn 14, Issue 5, 2014, Pages 601-616

  Hanke, Tomáš ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Conserved antigens; HIV; Prime boost; Vaccines

Indexed keywords

ANTIBODY; ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; VIRUS VECTOR; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY;

ADAPTIVE IMMUNITY; B LYMPHOCYTE; CD8+ T LYMPHOCYTE; DRUG DESIGN; EFFECTOR CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMORAL IMMUNITY; IMMUNE SYSTEM; MUTANT; NONHUMAN; PATHOGENESIS; REVIEW; VACCINATION; BIOSYNTHESIS; IMMUNOLOGY; INNATE IMMUNITY; T LYMPHOCYTE;

ADAPTIVE IMMUNITY; AIDS VACCINES; HIV ANTIBODIES; HIV-1; HUMANS; IMMUNITY, INNATE; T-LYMPHOCYTES;

EID: 84898716225     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2014.885946     Document Type: Review

References (189)

1. Plotkin SL, Plotkin S. A short history of vaccination. In: Plotkin S, Orenstein WA, Offit PA, editors, Vaccines, Elsevier-Saunders, Phildadelphia, PA; 2008. p. 1-6
2. Fenner F. A successful eradication campaign. Global eradication of smallpox. Rev Infect Dis 1982;4:916-30
3. World-Organisation-for-Animal-Health. Declaration of global eradication of rinderpest and implementation of follow-up measures to maintain world freedom from rinderpest. World Assembly of Delegates of the OIE. Paris, France; 2011
4. Plotkin SA. Vaccines: Correlates of vaccine-induced immunity. Clin Infect Dis 2008;47:401-9
5. Plotkin SA. Vaccines: The fourth century. Clin Vaccine Immunol 2009;16:1709-19
6. Koff WC, Burton DR, Johnson PR, et al. Accelerating next-generation vaccine development for global disease prevention. Science 2013;340:1232910
7. Rollier CS, Reyes-Sandoval A, Cottingham MG, et al. Viral vectors as vaccine platforms: Deployment in sight. Curr Opin Immunol 2011;23:377-82
8. Appay V, Douek DC, Price DA. CD8+ T cell efficacy in vaccination and disease. Nat Med 2008;14:623-8
9. Bojang KA. RTS,S/AS02A for malaria. Expert Rev Vaccines 2006;5:611-15
10. Deml L, Speth C, Dierich MP, et al. Recombinant HIV-1 Pr55gag virus-like particles: Potent stimulators of innate and acquired immune responses. Mol Immunol 2005;42:259-77
11. Stevens CE, Taylor PE, Tong MJ, et al. Yeast-recombinant hepatitis B vaccine. Efficacy with hepatitis B immune globulin in prevention of perinatal hepatitis B virus transmission. JAMA 1987;257:2612-16
12. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007;356:1928-43
13. Paavonen J, Jenkins D, Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: An interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007;369:2161-70
14. Wenger JD. Epidemiology of Haemophilus influenzae type b disease and impact of Haemophilus influenzae type b conjugate vaccines in the United States and Canada. Pediatr Infect Dis J 1998;17:S132-6
15. Reed SG, Bertholet S, Coler RN, et al. New horizons in adjuvants for vaccine development. Trends Immunol 2009;30:23-32
16. Buchbinder SP, Mehrotra DV, Duerr A, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): A double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008;372:1881-93
17. Gray G, Buchbinder S, Duerr A. Overview of STEP and Phambili trial results: Two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccine. Curr Opin HIV AIDS 2010;5:357-61
18. Gray GE, Allen M, Moodie Z, et al. Safety and efficacy of the HVTN. 503/ Phambili study of a clade-B-based HIV-1 vaccine in South Africa: A double-blind, randomised, placebo-controlled test-of-concept phase IIb study. Lancet Infect Dis 2011;11:507-15
19. Hammer SM, Sobieszczyk ME, Janes H, et al. Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N Engl J Med 2013;369:2083-92
20. Li F, Finnefrock AC, Dubey SA, et al. Mapping HIV-1 vaccine induced T-cell responses: Bias towards less-conserved regions and potential impact on vaccine efficacy in the step study. PLoS One 2011;6:e20479
21. Rappuoli R. Reverse vaccinology. Curr Opin Microbiol 2000;3:445-50
22. Donati C, Rappuoli R. Reverse vaccinology in the 21st century: Improvements over the original design. Ann NY Acad Sci 2013;1285:115-32
23. Van Regenmortel MHV. Synthetic peptide vaccines and the search for neutralization B cell epitopes. Open Vaccine J 2009;2:33-44
24. Gilbert SC, Plebanski M, Harris SJ, et al. A protein particle vaccine containing multiple malaria epitope. Nat Biotechnol 1997;15:1280-4
25. Hanke T, Schneider J, Gilbert SC, et al. DNA multi-CTL epitope vaccines for HIV and Plasmodium falciparum: Immunogenicity in mice. Vaccine 1998;16:426-35
26. Letourneau S, Im E-J, Mashishi T, et al. Design and pre-clinical evaluation of a universal HIV-1 vaccine. PLoS ONE 2007;2:e984
27. Rolland M, Nickle DC, Mullins JI. HIV-1 group M conserved elements vaccine. PLoS Pathog 2007;3:e157
28. McMichael AJ, Borrow P, Tomaras GD, et al. The immune response during acute HIV-1 infection: Clues for vaccine development. Nat Rev Immunol 2010;10:11-23
29. Altfeld M, Allen TM. Hitting HIV where it hurts: An alternative approach to HIV vaccine design. Trends Immunol 2006;27:504-10
30. Hanke T, McMichael AJ. HIV-1: From escapism to conservatism. Eur J Immunol 2011;41:3390-3
31. Kunwar P, Hawkins N, Dinges WL, et al. Superior control of HIV-1 replication by CD8+ T cells targeting conserved epitopes: Implications for HIV vaccine design. PLoS One 2013;8:e64405
32. Ekiert DC, Bhabha G, Elsliger MA, et al. Antibody recognition of a highly conserved influenza virus epitope. Science 2009;324:246-51
33. Rappuoli R. The challenge of developing universal vaccines. F1000 Med Rep 2011;3:16
34. Yewdell JW. Confronting complexity: Real-world immunodominance in antiviral CD8+ T cell responses. Immunity 2006;25:533-43
35. Abrahams MR, Anderson JA, Giorgi EE, et al. Quantitating the multiplicity of infection with human immunodeficiency virus type 1 subtype C reveals a nonpoisson distribution of transmitted variants. J Virol 2009;83:3556-67
36. Keele BF, Giorgi EE, Salazar-Gonzalez JF, et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci USA 2008;105:7552-7
37. Haase AT. Targeting early infection to prevent HIV-1 mucosal transmission. Nature 2010;464:217-23
38. Hansen SG, Piatak M Jr, Ventura AB, et al. Immune clearance of highly pathogenic SIV infection. Nature 2013;502:100-4
39. Hansen SG, Sacha JB, Hughes CM, et al. Cytomegalovirus vectors violate CD8+ T cell epitope recognition paradigms. Science 2013;340:1237874
40. Margolis DM, Hazuda DJ. Combined approaches for HIV cure. Curr Opin HIV AIDS 2013;8:230-5
41. Mongkolsapaya J, Dejnirattisai W, Xu XN, et al. Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. Nat Med 2003;9:921-7
42. Frahm N, Kiepiela P, Adams S, et al. Control of human immunodeficiency virus replication by cytotoxic T lymphocytes targeting subdominant epitopes. Nat Immunol 2006;7:173-8
43. Kiepiela P, Leslie AJ, Honeyborne I, et al. Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA. Nature 2004;432:769-75
44. Leslie A, Price DA, Mkhize P, et al. Differential selection pressure exerted on HIV by CTL targeting identical epitopes but restricted by distinct HLA alleles from the same HLA supertype. J Immunol 2006;177:4699-708
45. Ngumbela KC, Day CL, Mncube Z, et al. Targeting of a CD8 T cell env epitope presented by HLA-B 5802 is associated with markers of HIV disease progression and lack of selection pressure. AIDS Res Hum Retroviruses 2008;24:72-82
46. Kiepiela P, Ngumbela K, Thobakgale C, et al. CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med 2007;13:46-53
47. Masemola A, Mashishi T, Khoury G, et al. Hierarchical targeting of subtype C human immunodeficiency virus type 1 proteins by CD8+ T cells: Correlation with viral load. J Virol 2004;78:3233-43
48. Rolland M, Heckerman D, Deng W, et al. Broad and Gag-Biased HIV-1 Epitope Repertoires Are Associated with Lower Viral Loads. PLoS One 2008;3:e1424
49. Zuniga R, Lucchetti A, Galvan P, et al. Relative dominance of Gag p24-specific cytotoxic T lymphocytes is associated with human immunodeficiency virus control. J Virol 2006;80:3122-5
50. Mothe B, Llano A, Ibarrondo J, et al. Definition of the viral targets of protective HIV-1-specific T cell responses. J Transl Med 2011;9:208
51. Borthwick N, Ahmed T, Ondondo B, et al. Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1. Mol Ther 2013; In press . The first human trial testing a prophylactic T-cell vaccine focused on the conserved regions of HIV-1.
52. Kim HW, Canchola JG, Brandt CD, et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 1969;89:422-34
53. Kim HW, Leikin SL, Arrobio J, et al. Cell-mediated immunity to respiratory syncytial virus induced by inactivated vaccine or by infection. Pediatr Res 1976;10:75-8
54. McIntosh K, Fishaut JM. Immunopathologic mechanisms in lower respiratory tract disease of infants due to respiratory syncytial virus. Prog Med Virol 1980;26:94-118
55. Snape MD, Klinger CL, Daniels ED, et al. Immunogenicity and reactogenicity of a 13-valent-pneumococcal conjugate vaccine administered at 2, 4, and 12 months of age: A double-blind randomized active-controlled trial. Pediatr Infect Dis J 2007;29:e80-90
56. Fischer W, Perkins S, Theiler J, et al. Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. Nat Med 2007;13:100-6
57. Gaschen B, Taylor J, Yusim K, et al. Diversity considerations in HIV-1 vaccine selection. Science 2002;296:2354-60
58. Bihl F, Frahm N, Di Giammarino L, et al. Impact of HLA-B alleles, epitope binding affinity, functional avidity, and viral coinfection on the immunodominance of virus-specific CTL responses. J Immunol 2006;176:4094-101
59. Brockman MA, Chopera DR, Olvera A, et al. Uncommon pathways of immune escape attenuate HIV-1 integrase replication capacity. J Virol 2012;86:6913-23
60. Kijak GH, Currier JR, Tovanabutra S, et al. Lost in translation: Implications of HIV-1 codon usage for immune escape and drug resistance. AIDS Rev 2004;6:54-60
61. Price DA, West SM, Betts MR, et al. T cell receptor recognition motifs govern immune escape patterns in acute SIV infection. Immunity 2004;21:793-803
62. Schneidewind A, Brockman MA, Yang R, et al. Escape from the dominant HLA-B27-restricted cytotoxic Tlymphocyte response in Gag is associated with a dramatic reduction in human immunodeficiency virus type 1 replication. J Virol 2007;81:12382-93
63. Yerly D, Heckerman D, Allen TM, et al. Increased cytotoxic T-lymphocyte epitope variant cross-recognition and functional avidity are associated with hepatitis C virus clearance. J Virol 2008;82:3147-53
64. Lee JK, Stewart-Jones G, Dong T, et al. T cell cross-reactivity and conformational changes during TCR engagement. J Exp Med 2004;200:1455-66
65. Altfeld M, Addo MM, Rosenberg ES, et al. Influence of HLA-B57 on clinical presentation and viral control during acute HIV-1 infection. AIDS 2003;17:2581-91
66. Ferguson AL, Mann JK, Omarjee S, et al. Translating HIV sequences into quantitative fitness landscapes predicts viral vulnerabilities for rational immunogen design. Immunity 2013;38:606-17
67. Kelleher AD, Long C, Holmes EC, et al. Clustered mutations in HIV-1 gag are consistently required for escape from HLA-B27-restricted cytotoxic T lymphocyte responses. J Exp Med 2001;193:375-86
68. Leslie AJ, Pfafferott KJ, Chetty P, et al. HIV evolution: CTL escape mutation and reversion after transmission. Nat Med 2004;10:282-9
69. Rosario M, Bridgeman A, Quakkelaar ED, et al. Long peptides induce polyfunctional T cells against conserved regions of HIV-1 with superior breadth to single-gene vaccines in macaques. Eur J Immunol 2010;40:1973-84
70. Goonetilleke N, Liu MK, Salazar-Gonzalez JF, et al. The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J Exp Med 2009;206:1253-72
71. Walker B, McMichael A. The T-cell response to HIV. Cold Spring Harb Perspect Med 2012; doi: 10.1101/ cshperspect.a007054, [Accessed 21 September 2012]
72. Bansal A, Gough E, Sabbaj S, et al. CD8 T-cell responses in early HIV-1 infection are skewed towards high entropy peptides. AIDS 2005;19:241-50
73. Addo MM, Yu XG, Rathod A, et al. Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load. J Virol 2003;77:2081-92
74. Barouch DH, O'Brien KL, Simmons NL, et al. Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys. Nat Med 2010;16:319-23
75. Saunders KO, Rudicell RS, Nabel GJ. The design and evaluation of HIV-1 vaccines. AIDS 2012;26:1293-302
76. Depetris RS, Julien JP, Khayat R, et al. Partial enzymatic deglycosylation preserves the structure of cleaved recombinant HIV-1 envelope glycoprotein trimers. J Biol Chem 2013;287:24239-54
77. Julien JP, Cupo A, Sok D, et al. Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science 2013;342:1477-83
78. Ofek G, Guenaga FJ, Schief WR, et al. Elicitation of structure-specific antibodies by epitope scaffolds. Proc Natl Acad Sci USA 2010;107:17880-7
79. Porta C, Kotecha A, Burman A, et al. Rational engineering of recombinant picornavirus capsids to produce safe, protective vaccine antigen. PLoS Pathog 2013;9:e1003255
80. McLellan JS, Chen M, Joyce MG, et al. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science 2013;342:592-8
81. Burton DR, Poignard P, Stanfield RL, et al. Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses. Science 2012;337:183-6
82. Kwong PD, Mascola Jr. Human antibodies that neutralize HIV-1: Identification, structures, and B cell ontogenies. Immunity 2012;37:412-25
83. Scheid JF, Mouquet H, Ueberheide B, et al. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 2011;333:1633-7
84. Walker LM, Huber M, Doores KJ, et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 2011;477:466-70
85. Walker LM, Phogat SK, Chan-Hui PY, et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009;326:285-9
86. Zhou T, Georgiev I, Wu X, et al. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 2010;329:811-17
87. Haynes BF, Kelsoe G, Harrison SC, et al. B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. Nat Biotechnol 2012;30:423-33
88. Malherbe DC, Doria-Rose NA, Misher L, et al. Sequential immunization with a subtype B HIV-1 envelope quasispecies partially mimics the in vivo development of neutralizing antibodies. J Virol 2011;85:5262-74
89. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009;361:2209-20
90. Haynes BF, Gilbert PB, McElrath MJ, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 2012;366:1275-86
91. Karasavvas N, Billings E, Rao M, et al. The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120. AIDS Res Hum Retroviruses 2012;28:1444-57
92. Hanke T. On the growing complexity of HIV-1 vaccines. Future Gene Ther 2010;4:543-52
93. Pulendran B, Li S, Nakaya HI. Systems vaccinology. Immunity 2010;33:516-29
94. Pulendran B, Tang H, Manicassamy S. Programming dendritic cells to induce T(H)2 and tolerogenic responses. Nat Immunol 2010;11:647-55
95. Rhee EG, Blattman JN, Kasturi SP, et al. Multiple innate immune pathways contribute to the immunogenicity of recombinant adenovirus vaccine vectors. J Virol 2011;85:315-23
96. Schulz O, Diebold SS, Chen M, et al. Toll-like receptor 3 promotes crosspriming to virus-infected cells. Nature 2005;433:887-92
97. Hopkins R, Bridgeman A, Bourne C, et al. Optimizing HIV-1-specific CD8+ T-cell induction by recombinant BCG in prime-boost regimens with heterologous viral vectors. Eur J Immunol 2011;41:3542-52
98. Estcourt MJ, McMichael AJ, Hanke T. DNA vaccines against human immunodeficiency virus type 1. Immunol Rev 2004;199:144-55
99. Kopycinski J, Cheeseman H, Ashraf A, et al. A DNA-based candidate HIV vaccine delivered via in vivo electroporation induces CD4 responses toward the alpha4beta7-binding V2 loop of HIV gp120 in healthy volunteers. Clin Vaccine Immunol 2013;19:1557-9
100. Vasan S, Hurley A, Schlesinger SJ, et al. In vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteers. PLoS ONE 2011;6:e19252
101. Kalams SA, Parker SD, Elizaga M, et al. Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid interleukin 12 and impact of intramuscular electroporation for delivery. J Infect Dis 2013;208:818-29
102. Low L, Mander A, McCann K, et al. DNA vaccination with electroporation induces increased antibody responses in patients with prostate cancer. Hum Gene Ther 2009;20:1269-78
103. Bins AD, Jorritsma A, Wolkers MC, et al. A rapid and potent DNA vaccination strategy defined by in vivo monitoring of antigen expression. Nat Med 2005;11:899-904
104. McConkey SJ, Reece WH, Moorthy VS, et al. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat Med 2003;9:729-35
105. Kenter GG, Welters MJ, Valentijn AR, et al. Vaccination against HPV-16 Oncoproteins for Vulvar Intraepithelial Neoplasia. N Engl J Med 2009;361:1838-47
106. Welters MJ, Kenter GG, Piersma SJ, et al. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. Clin Cancer Res 2008;14:178-87
107. Rosario M, Borthwick N, Stewart-Jones GB, et al. Prime-boost regimens with adjuvanted synthetic long peptides elicit T cells and antibodies to conserved regions of HIV-1 in macaques. AIDS 2012;26:275-84
108. Kenter GG, Welters MJP, Valentijn RPM, et al. Vacination against Human Papilloma Virus 16 for vulvar intraepithelial neoplasia. N Engl J Med 2009;361:1838-47
109. Hansen SG, Vieville C, Whizin N, et al. Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat Med 2009;15:293-9
110. Patterson LJ, Malkevitch N, Venzon D, et al. Protection against mucosal simian immunodeficiency virus SIV(mac251) challenge by using replicating adenovirus-SIV multigene vaccine priming and subunit boosting. J Virol 2004;78:2212-21
111. Rose NF, Marx PA, Luckay A, et al. An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell 2001;106:539-49
112. Lorin C, Delebecque F, Labrousse V, et al. A recombinant live attenuated measles vaccine vector primes effective HLA-A0201-restricted cytotoxic T lymphocytes and broadly neutralizing antibodies against HIV-1 conserved epitopes. Vaccine 2005;23:4463-72
113. Yu W, Fang Q, Zhu W, et al. One time intranasal vaccination with a modified vaccinia Tiantan strain MVTT(ZCI) protects animals against pathogenic viral challenge. Vaccine 2010;28:2088-96
114. Parks CL, Picker LJ, King CR. Development of replication-competent viral vectors for HIV vaccine delivery. Curr Opin HIV AIDS 2013;8:402-11
115. Appaiahgari MB, Vrati S. Clinical development of IMOJEV (R)-A recombinant Japanese encephalitis chimeric vaccine (JE-CV). Expert Opin Biol Ther 2012;12:1251-63
116. Shiver JW, Emini EA. Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors. Annu Rev Med 2004;55:355-72
117. Baden LR, Walsh SR, Seaman MS, et al. First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001). J Infect Dis 2013;207:240-7
118. Barnes E, Folgori A, Capone S, et al. Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci Transl Med 2012;4:115ra1
119. Keefer MC, Gilmour J, Hayes P, et al. A phase I double blind, placebocontrolled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults. PLoS One 2012;7:e41936
120. Colloca S, Barnes E, Folgori A, et al. Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species. Sci Transl Med 2012;4:1-9
121. Dicks MDJ, Spencer AJ, Edwards NJ, et al. A novel chimpanzee adenovirus vector with low human seroprevalence: Improved systems for vector derivation and comparative immunogenicity. PLoS One 2012;7:e40385
122. Lasaro MO, Ertl HC. New insights on adenovirus as vaccine vectors. Mol Ther 2009;17:1333-9
123. Franchini G, Gurunathan S, Baglyos L, et al. Poxvirus-based vaccine candidates for HIV: Two decades of experience with special emphasis on canarypox vectors. Expert Rev Vaccines 2004;3:S75-88
124. Paoletti E, Tartaglia J, Taylor J. Safe and effective poxvirus vectors-NYVAC and ALVAC. Dev Biol Stand 1994;82:65-9
125. Tartaglia J, Perkus ME, Taylor J, et al. NYVAC: A highly attenuated strain of vaccinia virus. Virology 1992;188:217-32
126. Im E-J, Hanke T. MVA as a vector for vaccines against HIV-1. Expert Rev Vaccines 2004;3:S89-97
127. Greenough TC, Cunningham CK, Muresan P, et al. Safety and immunogenicity of recombinant poxvirus HIV-1 vaccines in young adults on highly active antiretroviral therapy. Vaccine 2008;26:6883-93
128. Robert-Guroff M. Replicating and nonreplicating viral vectors for vaccine development. Curr Opin Biotechnol 2007;18:546-56
129. Masopust D, Ha SJ, Vezys V, et al. Stimulation history dictates memory CD8 T cell phenotype: Implications for prime-boost vaccination. J Immunol 2006;177:831-9
130. Seder RA, Darrah PA, Roederer M. T-cell quality in memory and protection: Implications for vaccine design. Nat Rev Immunol 2008;8:247-58
131. Zagury D, Bernard J, Cheynier R, et al. A group specific anamnestic immune reaction against HIV-1 induced by a candidate vaccine against AIDS. Nature 1988;332:728-31
132. Zagury D, Leonard R, Fouchard M, et al. Immunization against AIDS in humans. Nature 1987;326:249-50
133. Hu SL, Abrams K, Barber GN, et al. Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160. Science 1992;255:456-9
134. Pal R, Venzon D, Santra S, et al. Systemic immunization with an ALVACHIV-1/protein boost vaccine strategy protects rhesus macaques from CD4+ Tcell loss and reduces both systemic and mucosal simian-human immunodeficiency virus SHIVKU2 RNA levels. J Virol 2006;80:3732-42
135. Barnett SW, Rajasekar S, Legg H, et al. Vaccination with HIV-1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 subunit. Vaccine 1997;15:869-973
136. Richmond JF, Lu S, Santoro JC, et al. Studies of the neutralizing activity and avidity of anti-human immunodeficiency virus type 1 Env antibody elicited by DNA priming and protein boosting. J Virol 1998;72:9092-100
137. Bansal A, Jackson B, West K, et al. Multifunctional T-cell characteristics induced by a polyvalent DNA prime/ protein boost human immunodeficiency virus type 1 vaccine regimen given to healthy adults are dependent on the route and dose of administration. J Virol 2008;82:6458-69
138. Wang S, Kennedy JS, West K, et al. Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers. Vaccine 2008;26:1098-110
139. Jiang G, Charoenvit Y, Moreno A, et al. Induction of multi-Antigen multi-stage immune responses against Plasmodium falciparum in rhesus monkeys, in the absence of antigen interference, with heterologous DNA prime/poxvirus boost immunization. Malar J 2007;6:135
140. Rogers WO, Baird JK, Kumar A, et al. Multistage multiantigen heterologous prime boost vaccine for Plasmodium knowlesi malaria provides partial protection in rhesus macaques. Infect Immun 2001;69:5565-72
141. McCormack S, Stohr W, Barber T, et al. EV02: A Phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C alone. Vaccine 2008;26:3162-74
142. Harari A, Bart PA, Stohr W, et al. An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J Exp Med 2008;205:63-77
143. Hel Z, Poudyal M, Tsai WP, et al. NYVAC-SIV vaccine-induced CD4 and CD8 T cell immune responses in SIV-infected macaques is dependent on the level of viremia. J Hum Virol 1999;2:181
144. Goonetilleke N, Moore S, Dally L, et al. Prime-boost vaccination with recombinant DNA and MVA expressing HIV-1 Clade A gag and immunodominant CTL epitopes induces multi-functional HIV-1-specific T cells in healthy subjects. J Virol 2006;80:4717-28
145. Hanke T, Goonetilleke N, McMichael AJ, et al. Clinical experience with plasmid DNA-And modified vaccinia vaccine Ankara (MVA)-vectored HIV-1 clade A vaccine inducing T cells. J Gen Virol 2007;88:1-12
146. Hayes P, Gilmour J, von Lieven A, et al. Safety and immunogenicity of DNA prime and modified vaccinia ankara virus-HIV subtype C vaccine boost in healthy adults. Clin Vaccine Immunol 2013;20:397-408
147. Mehendale S, Thakar M, Sahay S, et al. Safety and immunogenicity of DNA and MVA HIV-1 subtype C vaccine prime-boost regimens: A phase I randomised Trial in HIV-uninfected Indian volunteers. PLoS ONE 2013;8:e55831
148. Mwau M, Cebere I, Sutton J, et al. An HIV-1 clade A vaccine in clinical trials: Stimulation of HIV-specific T cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans. J Gen Virol 2004;85:911-19
149. Vuola JM, Keating S, Webster DP, et al. Differential immunogenicity of various heterologous prime-boost vaccine regimens using DNA and viral vectors in healthy volunteers. J Immunol 2005;174:449-55
150. Webster DP, Dunachie S, Vuola JM, et al. Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara. Proc Natl Acad Sci USA 2005;102:4836-41
151. Churchyard GJ, Morgan C, Adams E, et al. A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204). PLoS One 2011;6:e21225
152. Kibuuka H, Kimutai R, Maboko L, et al. A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172). J Infect Dis 2010;201:600-7
153. Jaoko W, Karita E, Kayitenkore K, et al. Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa. PLoS One 2010;5:e12873
154. Hanke T, Blanchard TJ, Schneider J, et al. Enhancement of MHC class Irestricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime. Vaccine 1998;16:439-45
155. Schneider J, Gilbert SC, Blanchard TJ, et al. Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat Med 1998;4:397-402
156. Moorthy VS, Imoukhuede EB, Keating S, et al. Phase 1 evaluation of 3 highly immunogenic prime-boost regimens, including a 12-month reboosting vaccination, for malaria vaccination in Gambian men. J Infect Dis 2004;189:2213-19
157. Ewer KJ, O'Hara GA, Duncan CJ, et al. Protective CD8(+) T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation. Nat Commun 2013;4:2836
158. O'Hara GA, Duncan CJ, Ewer KJ, et al. Clinical assessment of a recombinant simian adenovirus ChAd63: A potent new vaccine vector. J Infect Dis 2012;205:772-81
159. Sheehy SH, Duncan CJ, Elias SC, et al. Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors. PLoS One 2012;7:e31208
160. Sheehy SH, Duncan CJ, Elias SC, et al. ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: Assessment of efficacy against mosquito bite challenge in humans. Mol Ther 2013;20:2355-68
161. Sheehy SH, Duncan CJ, Elias SC, et al. Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors. Mol Ther 2012;19:2269-76
162. McShane H, Pathan AA, Sander CR, et al. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat Med 2004;10:1240-4
163. Tameris MD, Hatherill M, Landry BS, et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: A randomised, placebo-controlled phase IIb trial. Lancet 2013;381:1021-8
164. Hoft DF, Blazevic A, Stanley J, et al. A recombinant adenovirus expressing immunodominant TB antigens can significantly enhance BCG-induced human immunity. Vaccine 2012;30:2098-108
165. Chapman R, Chege G, Shephard E, et al. Recombinant Mycobacterium bovis BCG as an HIV vaccine vector. Curr HIV Res 2010;8:282-98
166. Honda M, Wang R, Kong WP, et al. Different vaccine vectors delivering the same antigen elicit CD8+ T cell responses with distinct clonotype and epitope specificity. J Immunol 2009;183:2425-34
167. Rosario M, Fulkerson J, Soneji S, et al. Safety and immunogenicity of novel recombinant BCG and modified vaccinia virus Ankara vaccines in neonate rhesus macaques. J Virol 2010;84:7815-21
168. Rosario M, Hopkins R, Fulkerson J, et al. Novel recombinant Mycobacterium bovis BCG, ovine atadenovirus, and modified vaccinia virus Ankara vaccines combine to induce robust human immunodeficiency virus-specific CD4 and CD8 T-cell responses in rhesus macaques. J Virol 2010;84:5898-908
169. Gray CM, Mlotshwa M, Riou C, et al. Human immunodeficiency virus-specific gamma interferon enzyme-linked immunospot assay responses targeting specific regions of the proteome during primary subtype C infection are poor predictors of the course of viremia and set point. J Virol 2009;83:470-8
170. Makedonas G and Betts MR. Living in a house of cards: Re-evaluating CD8+ T-cell immune correlates against HIV. Immunol Rev 2011;239:109-24
171. Fukazawa Y, Park H, Cameron MJ, et al. Lymph node T cell responses predict the efficacy of live attenuated SIV vaccines. Nat Med 2012;18:1673-81
172. Yamamoto T, Johnson MJ, Price DA, et al. Virus inhibition activity of effector memory CD8(+) T cells determines simian immunodeficiency virus load in vaccinated monkeys after vaccine breakthrough infection. J Virol 2012;86:5877-84
173. Freel SA, Lamoreaux L, Chattopadhyay PK, et al. Phenotypic and functional profile of HIV-inhibitory CD8 T cells elicited by natural infection and heterologous prime/boost vaccination. J Virol 2011;84:4998-5006
174. Freel SA, Picking RA, Ferrari G, et al. Initial HIV-1 antigen-specific CD8+ T cells in acute HIV-1 infection inhibit transmitted/founder virus replication. J Virol 2012;86:6835-46
175. Yang H, Wu H, Hancock G, et al. Antiviral inhibitory capacity of CD8+ T cells predicts the rate of CD4+ T-cell decline in HIV-1 infection. J Infect Dis 2012;206:552-61
176. Spentzou A, Bergin P, Gill D, et al. Viral inhibition assay: A CD8 T cell neutralization assay for use in clinical trials of HIV-1 vaccine candidates. J Infect Dis 2010;201:720-9
177. Pollard AJ, Savulescu J, Oxford J, et al. Human microbial challenge: The ultimate animal model. Lancet Infect Dis 2012;12:903-5
178. Ruprecht RM. Passive immunization with human neutralizing monoclonal antibodies against HIV-1 in macaque models: Experimental approaches. Methods Mol Biol 2009;525:559-66, xiv 179. Balazs AB, West Jr. A.P. Antibody gene transfer for HIV immunoprophylaxis. Nat Immunol 2013;14:1-5
179. Global vaccines pipeline capsule-2013. 2013. Available from: Http://www. researchandmarkets.com/reports/2336355/global-vaccines-pipeline-capsule-2013
180. Mbow ML, De Gregorio E, Valiante NM, et al. New adjuvants for human vaccines. Curr Opin Immunol 2011;22:411-16
181. Rolland M, Edlefsen PT, Larsen BB, et al. Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. Nature 2012;490:417-20
182. McMichael AJ, Haynes BF. Lessons learned from HIV-1 vaccine trials: New
183. Corey L, Nabel GJ, Dieffenbach C, et al. HIV-1 vaccines and adaptive trial designs. Sci Transl Med 2011;3:79ps13
184. Gilbert PB, Grove D, Gabriel E, et al. A sequential phase IIb trial design for evaluating vaccine efficacy and immune correlates for multiple HIV vaccine regimens. Stat Commun Infect Dis 2011;3(1). pii: 1037
185. Excler JL, Rida W, Priddy F, et al. A strategy for accelerating the development of preventive AIDS vaccines. Aids 2007;21:2259-63
186. McMichael A, Picker LJ, Moore JP, et al. Another HIV vaccine failure: Where to next? Nat Med 2013;19:1576-7
187. Flynn NM, Forthal DN, Harro CD, et al. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 2005;191:654-65
188. Pitisuttithum P, Gilbert P, Gurwith M, et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 2006;194:1661-71
189. Hill A. Plenary 03 of AIDS vaccine. Available from http://www. aidsvaxwebcasts.org/console/ player/21701?mediaType=audio& Partnership